Clinical Scorecard: Hypersensitivity to Granulocyte Colony-Stimulating Factor Associated with RUNX1 Haploinsufficiency
At a Glance
Category
Detail
Condition
Familial platelet disorder with predisposition to myeloid malignancies (FPD/MM) linked to RUNX1 haploinsufficiency
Key Mechanisms
RUNX1 haploinsufficiency leads to G-CSF hypersensitivity causing hematopoietic stem/progenitor cell expansion, mobilization, and myeloid differentiation block
Target Population
Patients with germline RUNX1 mutations, including familial platelet disorder patients and those at risk for myeloid leukemia
Care Setting
Hematology and oncology clinical settings, research laboratories studying hematopoiesis and leukemia predisposition
Key Highlights
RUNX1 mutations are common in acute leukemia and cause familial platelet disorder with leukemia predisposition.
Runx1+/− mice and FPD patient cells show hypersensitivity to G-CSF, leading to expansion and mobilization of immature hematopoietic progenitors.
G-CSF hypersensitivity may increase the pool of immature progenitors, raising the risk of acquiring mutations for leukemic transformation.
Guideline-Based Recommendations
Diagnosis
Identify germline RUNX1 mutations in patients with thrombocytopenia and family history of myeloid malignancies.
Use peripheral blood mononuclear cells to assess G-CSF hypersensitivity in suspected cases.
Management
Monitor patients with RUNX1 haploinsufficiency for hematopoietic abnormalities and leukemic progression.
Use G-CSF cautiously in patients with RUNX1 mutations due to potential hypersensitivity and altered hematopoiesis.
Monitoring & Follow-up
Regular hematologic evaluation including platelet counts and progenitor cell assessments.
Monitor for signs of myeloid differentiation block and expansion of immature progenitors.
Risks
Increased risk of leukemic transformation due to expanded immature progenitor pool under G-CSF stimulation.
Potential adverse effects of G-CSF treatment in RUNX1 haploinsufficient patients.
Patient & Prescribing Data
Patients with familial platelet disorder and RUNX1 haploinsufficiency
G-CSF administration induces hypersensitive hematopoietic responses; careful dosing and monitoring are essential to avoid excessive progenitor expansion and leukemic risk.
Clinical Best Practices
Confirm RUNX1 mutation status in patients with familial platelet disorder and leukemia predisposition.
Assess hematopoietic progenitor responses to G-CSF in vitro and in vivo to guide clinical decisions.
Avoid or carefully manage G-CSF therapy in RUNX1 haploinsufficient patients to mitigate leukemogenic risk.
Implement regular monitoring for hematopoietic abnormalities and early signs of leukemia development.
Now, as a member of the Transplant and Cellular Therapy team at Roswell Park, Chelsea Peterson, DO, is eager to see the continued evolution of cellular and CAR T-cell therapies for patients beyond just those with solid tumors.
